angiogenesis ͉ cancer ͉ nanoparticle
angiogenesis ͉ cancer ͉ nanoparticle M assive efforts to develop improved anticancer drugs have focused on high-throughput screening of large compound libraries. This is, in part, because of the relative lack of success achieved to date by using structure-based drug design against tumor targets. However, it is noteworthy that many anticancer drugs presently used in clinical practice are natural products (such as taxoids, vinca alkaloids, or anthracyclines) or are derivatives of natural products (such as etoposides) (1) . Therefore, the continued analysis of natural sources remains likely to reveal new and unexpected compounds with potential medical applications, which is supported not only by these prior successes but also by recent assessments of biodiversity (2) (3) (4) .
In this respect, metabolites from marine microorganisms provide a significant resource for the discovery of novel, small molecules for pharmaceutical and biomedical applications (5, 6) . Lyngbya majuscula in particular has been extensively studied and has produced Ͼ250 different compounds with diverse structural features (7, 8) . This diversity is in part attributable to the fact that a major theme in L. majuscula biochemistry relies on the production of metabolites via polyketide synthases and nonribosomal peptide synthetases within specialized biosynthetic pathways (9) . Here, we describe the activity and mechanism of action of a lipopeptide derived from L. majuscula, somocystinamide A (ScA), that potently induces apoptosis in tumor and angiogenic endothelial cells. Although ScA initiates apoptosis via both the intrinsic and extrinsic pathways, the more sensitive pathway involves activation of caspase 8, which requires concentrations in the low nanomolar range and below, to initiate alterations in the cell membrane and apoptosis. The selective activation of the caspase 8 pathway by a small molecule is promising, because few currently used anticancer agents have this property. Many malignant tumors maintain expression of caspase 8, suggesting it may be an attractive target for tumor suppression (10) . Importantly, ScA possesses intrinsically attractive chemical properties, including a unique but readily synthesized structure and the capacity to spontaneously incorporate into lipid nanoplatforms while retaining proapoptotic activity. It would seem that such properties may be an asset for delivery via targeted nanoparticles, which is currently under development for clinical use.
Results

ScA Induces Apoptosis Selectively via Caspase 8.
In initial studies, we reported that ScA isolated from mixed assemblage L. majuscula/ Schizothrix species yielded modest cytotoxic effects against a murine neuroblastoma cell line (11) . Initial studies were somewhat limited by the relatively low abundance of this compound. In continuing investigations, we now document that freshly isolated ScA shows potent antiproliferative activity against a number of human tumor cells (Table 1) . Microscopic examination reveals that the loss of proliferation is associated with a ''blebbing'' morphology ( Fig. 1 A and B) , whereas biochemical analysis revealed proteolytic processing of cellular proteins, such as caspase 8 and poly(ADP-ribose) polymerase (PARP), that are hallmark indicators of apoptosis (Fig. 1C) . To determine whether caspase 8 expression could account for increased ScA activity, we examined the ability of ScA to induce apoptosis in wild-type Jurkat cells or those deficient in caspase 8. Compared with wild-type cells, apoptosis was dramatically decreased among caspase-8-deficient Jurkat cells exposed to ScA (Fig. 1D) . Extending these studies, we knocked down expression of caspase 8 (Ϸ80%) by using a short-hairpin RNA (shRNA) approach in the A549 cell line and found a 5-fold loss in sensitivity to ScA (Fig. 1E) . Finally, we also tested NB7 neuroblastoma tumor cells, which are deficient for caspase 8 expression, and the matched sister line, NB7C8, which is reconstituted for physiological levels of caspase 8 expression (12) . In this case, the expression of caspase 8 increased the potency (IC 50 ) of ScA by 50-fold (Fig.  1F) . The results implicate caspase 8 as an effector of apoptosis after ScA treatment.
Caspase 8 is an effector of death receptor (DR)-mediated apoptosis after DR ligation by an appropriate agonist, which triggers the recruitment of the adaptor protein FADD and subsequent formation of the death-inducing signaling complex (13) . Accordingly, Jurkat cells lacking FADD were protected from ScA-mediated killing (Fig. 1D) , implicating DRmediated killing in this process. However, NB7C8 cells are resistant to DR-mediated killing (12) , and similarly A549 cells do not undergo Fas-mediated apoptosis (ref. 14; our unpublished results), although both cell lines were sensitive to ScA-induced killing. In agreement with these results, the addition of the Fas agonist CH11 did not cooperate with ScA to promote cell death [see supporting information (SI)]. However, DR ''ligation'' is not strictly required for apoptosis induced by DRs; rather, it appears that ligand-mediated redistribution of membrane components may be critical to trigger cell death (15) (16) (17) .
ScA Partitions into Phospholipids and Alters Membrane Structure.
The delivery of drugs via liposomes is clinically relevant (18) . Because ScA is a lipophilic compound (logP ϭ 10.3), we assessed the capacity of ScA to partition from liquid phase into 100-nm liposomes (nanosomes). Remarkably, interchelation of ScA within the nanosomes was essentially complete within 30 min, with no residual unincorporated drug detected (data not shown). Testing whether the liposome-borne ScA maintained cytotoxic activity, we found that apoptosis induced by treatment of cells with ScA nanosomes mimicked treatments with ScA as a ''free'' compound (Fig. 2B) . Treatment with control, unloaded nanosomes had no effect on cell viability. Together, these results support the potential for future nanosome-based delivery of ScA in vivo, whereas implicating the lipid compartment in ScAmediated cell death.
In this respect, it is known that alterations to the cell lipid compartment can promote caspase-mediated cell killing. For example, ceramide-enriched membrane domains can promote DR clustering and activation of caspase 8 (17, 19, 20) , whereas treatment with arachidonic acid can mediate caspase-3-dependent cell death (21) . Therefore, we examined the A549 cells for evidence of alteration to the lipid compartment after exposure to ScA. Interestingly, we observed an accumulation, and aggregation, of cell surface ceramide (Fig. 2B , red channel) that was absent among cells treated with diluent (our unpublished results) or those treated with arachidonic acid (control) (Fig. 2B ). This result supported the notion that ScA acted via alterations to the plasma membrane. To evaluate whether observed alterations to membrane lipid distribution corresponded to interactions with apoptotic effectors, in particular caspase 8, we next examined whether these aggregated ''clusters'' of ceramide in the membrane colocalized with this caspase (Fig. 2B , green channel; colocalization is shown in the yellow channel). The results supported the notion that ScA partitions within cell membranes, alters the lipid compartment and induces the external death pathway in susceptible cells. Although ceramide was used as a reporter of changes within the organization of the lipid compartment, it remains unclear which lipids (if any) directly contribute to apoptosis. However, it was not simply the lipophilic nature of ScA that resulted in proapoptotic activity. ScA is a disulfide-linked lipopeptide dimer (Fig. 2C) , and in parallel structure-function studies we found that individual monomers retained essentially no ability (Ͻ0.1% potency) to induce apoptosis. Similarly, chemical modification of either the lipopeptide tail of the molecule or manipulations of the disulfide bond abrogated all tumoricidal activity of the compound. Thus, the combination of lipopeptide and disulfide moieties appears critical to ScA activity.
Antiangiogenic and Antitumoral Effects of ScA. Angiogenic endothelial cells are susceptible to apoptosis initiated by caspase 8 (20, 22, 23) . We therefore tested the effect of ScA treatment on endothelial cells in vitro and in vivo. Cultured endothelial cells were extremely sensitive to ScA (Fig. 3A) , with an IC 50 in the picomolar range. In agreement with these results, we found that ScA potently blocked endothelial cell tube formation in vitro (Fig. 3B) , suggesting that ScA might act both on endothelial and on tumor cells in vivo.
To test this, we first examined whether systemic exposure to ScA blocked developmental angiogenesis in zebrafish. During development of the zebrafish, intersegmental vessels sprout and grow upwards from the dorsal aorta, and then the tips join to form a dorsal vein (Fig. 4A) . In a dose-dependent manner (Fig.  4 B-F) , ScA blocked blood vessel growth and angiogenesis, although all of the fish remained viable during the 24-h period of the study. Similarly, local introduction of ScA into the chick chorioallantoic membrane potently blocked growth-factorinduced angiogenesis (Fig. 4G) .
To tested the capacity of ScA to directly inhibit tumor growth in vivo, neuroblastoma tumors expressing (or lacking) caspase 8 were seeded into the chick chorioallantoic membrane, and a tumor mass was allowed to establish for 3 days. Tumors then were treated topically with 100 pmol of ScA and allowed to grow a further 5 days before being harvested. In this case, we observed an inhibition of tumor growth selectively in the caspase-8-expressing tumor cells. The results show that, in addition to an antiangiogenic effect, low levels of ScA also can act to inhibit the growth of caspase-8-expressing tumor cells.
Discussion
The genetic diversity in the world's oceans recently has become more widely appreciated (2-4, 24, 25) . In particular, the diversity of biochemical matter that arises from unique and previously uncharacterized metabolic pathways holds promise for the development of new compounds in the treatment of human malignancy. This study focuses on the activity of ScA, a lipopeptide derived from the cyanobacteria L. majuscula (26, 27) . We show here that ScA selectively activates a caspase-8-dependent cell death pathway. Interestingly, apoptosis occurs among tumor lines that are normally resistant to treatment with DR agonists that act via caspase 8, which is of particular interest because many tumors tend to maintain caspase 8 expression, likely because of its ability also to fulfill nonapoptotic roles (10, 28) , but are resistant to DR-mediated killing (29) . Other natural products, including the complex heterocycle gambogic acid (30) and the related kaurene diterpene (31), also activate caspase-8-dependent killing. Although gambogic acid is structurally unrelated to ScA and acts via distinct molecular pathways (30) , the shared property of caspase 8 activation is interesting, and it is conceivable that such compounds could function as defensive adaptations (9) .
ScA induces alterations in the plasma membrane lipid compartment, as indicated by clustering of ceramide on the cell surface associated with activation of caspase 8 and cell death. At micromolar concentrations, ScA can induce cell death via caspase-8-independent pathways, as shown by its capacity to induce apoptosis in caspase-8-deficient cells. This finding is in agreement with other lipid agents, such as ceramide, which can induce apoptosis via several different actions (19, 32) . Nonetheless, the cytotoxic actions of ScA at nanomolar and picomolar concentrations are caspase-8-dependent. Our results group the cell lines examined into two categories: those that are sensitive in the lower nanomolar ranges and those in which near-micromolar and above concentrations are required to induce cell death ( Table 1 ). All of the more sensitive lines can be killed by caspase-8-mediated pathways. However, we expect that metabolic pathways that regulate the lipid composition of the plasma membrane will also act as independent factors that can modulate cell sensitivity to ScA. ScA contains a disulfide bond that is anticipated to be reduced upon exposure to the inner leaflet of the plasma membrane. However, it is not yet clear whether covalent modification of membrane components by ScA is necessary to activate (or inactivate) ScA-mediated killing. ScA does represent an uncommon structure among compounds isolated from marine cyanobacteria, containing a disulfide moiety and lipopeptide tails, and the cytotoxic activity of ScA requires both lipopeptide and disulfide moieties to initiate caspase-8-dependent death. Truncation of the lipopeptide, or reduction or substitution of the sulfhydryl bonds, abrogated the cytocidal activity of ScA. However, ScA integrated into nanosomes maintained full activity, suggesting an alternative mechanism for delivery in which ScA would be sequestered and protected within a hydrophobic environment, which may be particularly desirable for in vivo applications, based on the ability of liposomes to stabilize and provide a targeting function for ScA. For example, interchelation within nanosomes would be expected to protect the disulfide bond moiety from metabolic degradation after administration in vivo. Thus, nanosomes are an attractive candidate for preclinical delivery of ScA.
Synthesis of ScA involves known organic chemistry reactions and can be accomplished via more than one approach. Currently, we are investigating two distinct reaction schemes to optimize yield and purity for future large-scale production. Storage of ScA in an inert dry atmosphere is anticipated to be necessary to avoid eventual hydrolytic degradation of the unsaturated amide, but the compound is otherwise quite stable. Similarly, the production of the nanosomes involves the assembly from commercially available structural and targeting components, and occurs in quantitative yields via standard liposome production techniques. Thus, ScA represents an active natural compound that appears unencumbered by issues with complex synthesis or upscaling commonly associated with natural products.
The optimization of targetable nanoplatforms that home to specific tumor or vascular beds is rapidly proceeding (33) . This therapeutic approach will benefit from both pro-drug approaches and from drugs, such as ScA, that show limited solubility in aqueous media and act directly at the plasma After 72 h, ScA was added topically to each growing tumor mass. Tumors were harvested and resected on day 8, and mass (wet weight) was determined. Data shown is the mean Ϯ SD (n ϭ 8 -12). The mass of the NB7C8 is significantly decreased (P Ͻ 0.002).
membrane of susceptible cells. Toxic and relatively insoluble drugs, such as taxols, may find advantages conferred by nanoplatform-mediated delivery. Similarly, we expect that the ability of ScA to readily partition within the nanosome lipid component is advantageous for the targeted delivery of this compound to tumors. The targeted nanosome strategy overcomes some issues in terms of solubility and metabolism of ScA while in circulation. In turn, drugs such as ScA do not compete for interior ''cargo'' space designated for soluble drug payloads. We speculate that such approaches therefore may represent an efficient design for the delivery of combination therapies. Given the sensitivity of proliferating endothelial cells to ScA, it is likely that targeted delivery to cells of the vascular compartment will promote a potent and specific antiangiogenic response.
Materials and Methods
Confocal Microscopy. For confocal analysis, A549 cells were seeded on glass coverslips, treated with ScA, DMSO, or arachidonic acid (controls) at 1 or 0.1 M concentration for 30 min or 6 h. After treatment, the cells were fixed for 10 min at room temperature with 4% paraformaldehyde, washed twice with PBS, permeabilized for 2 min at room temperature with 0.1% Triton in PBS, and blocked for 30 min with sterile 2% BSA in PBS. The staining was performed at room temperature for 2 h, with mouse monoclonal anti-human ceramide (Alexis) and rabbit anti-human caspase 8 (BD PharMingen) antibodies followed by secondary goat anti-mouse Alexa Fluor 568 and goat anti-rabbit Alexa Fluor 488 antibodies (Invitrogen). The blue DNA binding dye TOPRO-3 (Molecular Probes) was added together with the secondary antibodies. The cells were washed three times with PBS between the different incubation steps, and the incubation with the secondary fluorescently labeled antibodies was performed in the dark. All antibodies were diluted in PBS. Confocal images were recorded on a Nikon Eclipse C1 confocal microscope. Cytotoxicity Assay. Cytotoxicity of ScA was assessed by using the XTT cell proliferation assay. Briefly, cells were plated on 96-well plates (5,000 per well) and incubated overnight at 37°C to allow for attachment and spreading. After 24 h, ScA was added from a DMSO stock, previously frozen at Ϫ80°C, as added directly from serial dilutions in DMSO at concentrations ranging from 100 M to 100 fM. After 72 h, XTT (Aldrich Chemicals) was added to a final concentration of 250 g per well. The plates then were incubated under standard tissue culture conditions until the control wells (DMSO) reached an OD value between 1.0 and 1.5. as measured at 450 nm with a microtiter plate reader. The cell viability-drug dilution profiles were obtained from sigma plots, and drug concentrations that inhibited growth by 50% were calculated from multiple runs (IC50).
Preparation of Liposomes. Cholesterol:1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE):1,2-dioleoyl-sn-glycero-3-phosphocholine (DSPC):scA:1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethyleneglycol)-2000] ammonium salt (DSPE-mPEG) (in 1:1:1:0.16:0.16 molar ratio) in chloroform were taken in 30-ml glass culture tubes, dried under a stream of nitrogen gas, and vacuum-desiccated for a minimum of 6 h to remove any residual organic solvent. The dried lipid film was hydrated in sterile deionized water in a total volume of 1 ml for a minimum of 12 h. Liposomes were vortexed for 2-3 min to remove any adhering lipid film and sonicated in a bath sonicator (ULTRAsonik 28X) for 2-3 min at room temperature to produce multilamellar vesicles (MLVs). MLVs then were sonicated with a Ti-probe (using a Branson 450 Sonifier at 100% duty cycle and 25 W output power) in an ice bath for 1-2 min to produce small unilamellar vesicles (SUVs) as indicated by the formation of a clear translucent solution. The solution was pressure-filtered in sequence through 200-nm and then 100-nm nucelopore polycarbonate membranes to obtain liposome nanoparticles of 100 nm with a polydispersity factor of Ͻ0.1. Endothelial Cell Tube Formation. Next, 96-well plates were coated with 200 l of Matrigel per well and stored at 4°C until use. Human umbilical vein endothelial cells (HUVECs) were harvested, and cell suspensions were prepared at a density of 200,000 per ml, and added at 100 l per well to the plates. ScA in DMSO were added to each well at 10 nM, 100 pM, and 1 pM concentrations with 1% DMSO as control. The plates were incubated at 37°C under standard incubator conditions, and the results were observed microscopically for tube formation.
Zebrafish Experiments. Blood vessel formation in zebrafish was as follows. Transgenic Tg(fli1:EGFP) zebrafish embryos were purchased from The Zebrafish Model Organism Database (www.zfin.org) as reported in ref. 35 . Adult fish and embryos were maintained according to Zebrafish: A Practical Approach (36) . ScA as a DMSO stock solution was diluted directly into the water, and zebrafish intersegmental vessels were imaged with a Nikon c1-si confocal microscope after the times specified. Raw image datasets were processed by using Imaris 3D image analysis software (www.bitplane.com). All animal procedures were conducted in accordance with all appropriate regulatory standards under protocol S06008 approved by the UCSD Institutional Animal Care and Use Committee.
Chick Chorioallantoic Membrane Studies. The chorioallantoic membrane studies were performed by using 10-day-old chick embryos as described in ref. 37 . For the tumor studies, 5 ϫ 10 6 NB7 or NB7C8 neuroblastoma tumor cells were seeded into the chorioallantoic membranes on 10-day-old embryos and the tumor allowed to develop until day 18 (12) .
Western Blotting Analysis. Cells were treated as indicated and extracts were prepared by lysis in RIPA buffer (100 mM Tris, pH 7.5/150 mM NaCl/1 mM EDTA/1% deoxycholate/1% Triton X-100/0.1% SDS/50 mM NaF/complete protease inhibitor; Roche Molecular Biochemicals) on ice. Cell extracts (25 g) were resolved by 8% SDS/PAGE, transferred to nitrocellulose, and probed with antibodies. Caspase 8 was probed with polyclonal antibody from (Millipore) or affinity-purified catalytic domain-specific antisera (C8 -531) prepared at UCSD. Caspase-3 (MAB4703, 1:500; Chemicon), caspase 9 (sc17784, 1:100; Santa Cruz Biotechnology), actin (1:5,000; Sigma), and PARP (sc556493, 1:500; Santa Cruz Biotechnology) were probed with mouse monoclonal antibodies. Bound antibodies were detected with horseradish peroxidase-conjugated secondary antibodies (BioRad) and the ECL system (Pierce).
FACS Analysis.
Cell viability was analyzed by flow cytometry after propidium iodide (PI) staining, as described in ref. 38 . Briefly, after each treatment, cells were harvested in ice-cold PBS, washed two times in PBS at 4°C, and resuspended in 10 g/ml PI. The extent of apoptosis was determined by plotting PI fluorescence versus the forward-scatter parameter with Cell Quest software.
